Publications
332 publications
Sort by: Date / Relevance
Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
Zorginstituut Nederland has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) and two ...
Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)
Zorginstituut Nederland has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).
GVS advice on subcutaneous buprenorphine (Buvidal®)
Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...
Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)
Zorginstituut Nederland has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in the insured ...
Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma
Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...
Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...
GVS assessment of calcifediol (Hidroferol®)
Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...
Package advice niraparib (Zejula®)
Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...
GVS advice SGLT-2 inhibitors
Zorginstituut Nederland has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin (Invokana®), ...
GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia
Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...